Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers.
about
Novel automated blood separations validate whole cell biomarkersModeling Barrier Tissues In Vitro: Methods, Achievements, and ChallengesLong-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic reviewThe Corticospinal Tract: A Biomarker to Categorize Upper Limb Functional Potential in Unilateral Cerebral PalsyExploring the effects of polymorphisms on cis-regulatory signal transduction responseThe genetics of complex cholestatic disordersPersonalized medicine using DNA biomarkers: a reviewUsing Periostin as a Biomarker in the Treatment of AsthmaCost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in GermanyApplying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the futureUtilization of genomic signatures to identify phenotype-specific drugsHow bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public healthPrognosis research strategy (PROGRESS) 4: stratified medicine researchPrognosis Research Strategy (PROGRESS) 2: prognostic factor researchThe Translational Medicine Ontology and Knowledge Base: driving personalized medicine by bridging the gap between bench and bedsideAn Altered Treatment Plan Based on Direct to Consumer (DTC) Genetic Testing: Personalized Medicine from the Patient/Pin-cushion Perspective.Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkersMeta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data.Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development.Miniaturized pre-clinical cancer models as research and diagnostic tools.Conceptual and Analytical Considerations toward the Use of Patient-Reported Outcomes in Personalized MedicineCurrent challenges in health economic modeling of cancer therapies: a research inquiry.Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?Quantifying factors for the success of stratified medicine.Biomarkers and clinical staging in psychiatryAligning the economic value of companion diagnostics and stratified medicines.What have we learned about trial design from NIMH-funded pragmatic trials?Optimization of personalized therapies for anticancer treatmentHeterogeneity in action: the role of passive personalization in comparative effectiveness research.Personalizing health care: feasibility and future implications.Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial.Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder.New perspectives on chinese herbal medicine (zhong-yao) research and developmentQuantitative stratification of diffuse parenchymal lung diseases.Comparing different scientific approaches to personalized medicine: research ethics and privacy protection.Gender-specific cytokine pathways, targets, and biomarkers for the switch from health to adenoma and colorectal cancer.Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015.Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and FrailtyWhole body cardiovascular magnetic resonance imaging to stratify symptomatic and asymptomatic atherosclerotic burden in patients with isolated cardiovascular disease.
P2860
Q21560950-89DC0784-93B3-44AC-AD5D-45B751F06E67Q26748486-5C0A8EA0-5CA1-4086-84C4-9DD2EE5A1FB3Q26770497-441C0844-5433-42D3-B714-B3DF03A8AD02Q26771355-7687CC33-4B67-41A5-B4BA-4B1B95D32011Q26991710-306EF103-3C05-4163-A7D8-4E00690B45FEQ26992279-2CD64A71-4351-4EE9-BDEE-D2F6C8EAC05FQ27022319-E116822E-C30B-4603-814E-FCAE80675A26Q28067637-6886A46B-A1B1-4795-AD46-DD8395FA2583Q28072203-9FE72A18-1AAF-42CA-9489-0DE3CD78C6D3Q28074451-B41D4E37-367F-4A9A-BAA6-37CA1278ED12Q28476014-90D55FAE-3D9D-42E4-92DA-09EC6D00B7B3Q28649612-F57D4FBF-573C-4206-8BC1-7FC0BB4B84B9Q28709167-251A0B21-0305-4D34-911F-3A8113C9E10EQ28709212-8D32C2B8-5E4F-4BCF-8FEE-1B6A6C78BA7DQ28744215-17E7F339-C095-4ED0-97C5-18A84BB91C13Q30409124-D8B1A1B2-3C12-4DDE-8C8A-774ECF633EB8Q30570744-76BBE51C-5517-4329-BC8F-41EA033E6A3CQ30585374-2E64624F-B03B-4043-B8D8-EC49DF4D5314Q31017820-093C211B-DDFD-4605-B973-9030443C20BDQ33605145-014825D9-B9D4-4802-8224-CE182C971A10Q33714815-A8467F85-9382-455E-8437-49F46F7638B4Q33805471-77CFC05C-5EE9-4038-9FFF-4D8817F23DA9Q33963735-A9686C65-A4F2-4D5C-A458-6C287F9980B3Q34228544-59EA2AE9-A914-4D41-8633-D94ECD8335ACQ34447051-5C50B6BE-FB5C-4B44-8A79-49F5BF31DB71Q34608624-FCA30804-E004-4820-A395-CDFD10952421Q34661439-B17D7AF5-F1E7-4A23-827A-7E93D905D048Q34669425-8CD682BD-5F73-4E2C-962B-7C22669CD848Q34810548-6C56ABF1-928C-407A-919C-F1EE33884429Q34938911-39B10D8A-B05B-4451-89DE-EC7F490D642FQ35026973-B5D1D3F0-1391-4E67-9C3A-6445E95A8B8EQ35044690-74DAB638-61BF-436D-89C3-8D9C97B4013EQ35059381-CCD4C9A5-D56C-4F6E-99C6-30D00BC20966Q35102748-C00DDCFC-8DF5-4C4A-BD79-5368476867C6Q35133606-D899C3A7-207B-453B-8D70-9A9CFBA00071Q35188750-0CBD02F6-325C-40C6-A760-147F144FDD6FQ35659961-0A01379E-FD43-4E64-AA7E-904ABA9FBAB0Q35835158-B14246D8-6E19-47C5-AB80-D147E03A2C36Q35894623-E91624C7-0334-4E3D-8BB2-D9798D0A2FF1Q35938672-F66F9F93-EEE2-49C2-A5E0-31DE86208AF6
P2860
Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Stratified medicine: strategic ...... drugs and clinical biomarkers.
@ast
Stratified medicine: strategic ...... drugs and clinical biomarkers.
@en
type
label
Stratified medicine: strategic ...... drugs and clinical biomarkers.
@ast
Stratified medicine: strategic ...... drugs and clinical biomarkers.
@en
prefLabel
Stratified medicine: strategic ...... drugs and clinical biomarkers.
@ast
Stratified medicine: strategic ...... drugs and clinical biomarkers.
@en
P2093
P356
P1476
Stratified medicine: strategic ...... drugs and clinical biomarkers.
@en
P2093
Ernst R Berndt
Frank L Douglas
Mark R Trusheim
P2888
P304
P356
10.1038/NRD2251
P577
2007-04-01T00:00:00Z